uploads/2017/11/Ibrance.png

How Have Pfizer’s Ibrance and Sutent Performed in 2017?

By

Updated

Ibrance revenue trends

In 3Q17, Pfizer’s (PFE) Ibrance generated revenues of $878 million, a ~60% increase on year-over-year (or YoY) basis and ~3% growth on a quarter-over-quarter basis. In 3Q17, in the US market, Ibrance generated revenues of $713 million compared to $531 million in 3Q16, reflecting 34% growth on a YoY basis.

During the first nine months of 2017, Ibrance generated revenues of $2.4 billion, ~61% growth on a YoY basis. Ibrance’s competitors include Novartis’s (NVS) Afinitor, Roche’s (RHHBY) Herceptin, Kadcyla, and Perjeta. In 3Q17, Afinitor, Herceptin, Kadcyla, and Perjeta reported revenues of $389 million, $1.7 billion, $228 million, and $552 million, respectively.

Sutent revenue trends

In 3Q17, Sutent generated revenues of $276 million, a ~6% increase on a YoY basis and a 1% decline on a quarter-over-quarter basis. In 3Q17, in the US markets and in international markets, Sutent generated revenues of $87 million and $189 million, respectively, which reflected ~4% and ~7% growth on a YoY basis.

Sutent reported year-to-date September 2017 revenues of $805 million, a 2% decline on a YoY basis. In November 2017, the US Food and Drug Administration approved the label expansion of Pfizer’s Sutent to include it as an adjuvant treatment for individuals who are at high risk of recurrent renal carcinoma (or RCC) after nephrectomy.

The US FDA approval of Sutent was based on the results of the S-TRAC trial. Pfizer conducted the phase 3 S-TRAC trial to evaluate the safety and efficacy of Sutent as an adjuvant treatment for patients who are at high risk of recurrent RCC post nephrectomy.

In the phase three S-TRAC trial, Sutent demonstrated a median disease-free survival (or DFS) of 6.8 years compared to 5.6 years for patients on a placebo therapy. In the trial, Sunitinib demonstrated a DFS rate of 59.3% after five years compared to 51.3% for the placebo therapy.

Sutent competes with Bristol-Myers Squibb’s (BMY) Opdivo, Bayer’s Nexavar, and Roche’s Avastin.

The growth in sales of Ibrance and Sutent could boost the Vanguard S&P 500 ETF (VOO). Pfizer makes up about ~0.96% of VOO’s total portfolio holding.

More From Market Realist